What is BCLI's health score?

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) has a TradeApes health score of 52 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is BCLI's estimated fair value?

Based on our 5-year discounted cash flow model, BRAINSTORM CELL THERAPEUTICS INC.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is BCLI undervalued or overvalued?

Our model currently rates BCLI as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for BCLI... Refresh in a moment for the full analysis.

BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Healthcare Inconclusive inconclusive mixed

$0.75

Updated: 2026-06-06

TradeApes Score

Financial Strength

50 Mixed

Operating Trend

60 Healthy

Relative Value

40 Weak

Capital Allocation

40 Weak

Risk

80 Strong

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Weak liquidity — current assets below current liabilities

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.